CD274 and neoplasm: In the phase I study of anti-PD-L1 molecule on metastatic bladder cancer, patients with PD-L1 protein-positive tumors were selected for treatment with anti-PD-L1 mono-antibody if more than 5% of PD-L1+ tumor-infiltrating immune cells were detected in pretreatment archival tumor samples.